Sionna Therapeutics (NASDAQ:SION) Upgraded at Lifesci Capital

Sionna Therapeutics (NASDAQ:SION) was upgraded by equities researchers at Lifesci Capital to a “strong-buy” rating in a research report issued on Wednesday,Zacks.com reports.

Several other research analysts have also recently weighed in on SION. Royal Bank Of Canada reiterated an “underperform” rating and set a $24.00 price objective on shares of Sionna Therapeutics in a research report on Monday, December 1st. Weiss Ratings restated a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. BTIG Research reiterated a “buy” rating and issued a $58.00 price objective on shares of Sionna Therapeutics in a research note on Wednesday, January 14th. Citizens Jmp initiated coverage on shares of Sionna Therapeutics in a research report on Tuesday. They set a “market outperform” rating and a $63.00 target price on the stock. Finally, Citigroup started coverage on shares of Sionna Therapeutics in a report on Tuesday. They set an “outperform” rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $47.63.

Sionna Therapeutics Trading Up 1.9%

Sionna Therapeutics stock opened at $38.03 on Wednesday. The company has a market capitalization of $1.70 billion and a price-to-earnings ratio of -7.81. Sionna Therapeutics has a 12 month low of $7.26 and a 12 month high of $45.00. The stock’s 50 day moving average is $40.02 and its 200-day moving average is $34.79.

Insider Buying and Selling

In other Sionna Therapeutics news, Director Orbimed Advisors Llc sold 29,063 shares of the stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $44.58, for a total transaction of $1,295,628.54. Following the sale, the director directly owned 3,530,702 shares in the company, valued at $157,398,695.16. This represents a 0.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Tpg Gp A, Llc sold 250,000 shares of the firm’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $40.00, for a total transaction of $10,000,000.00. Following the completion of the transaction, the insider directly owned 6,494,962 shares in the company, valued at approximately $259,798,480. This represents a 3.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 382,368 shares of company stock valued at $15,898,607 over the last quarter. 3.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Sionna Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. acquired a new stake in shares of Sionna Therapeutics in the 3rd quarter valued at $30,000. BNP Paribas Financial Markets bought a new stake in shares of Sionna Therapeutics during the 2nd quarter worth $31,000. GF Fund Management CO. LTD. bought a new stake in shares of Sionna Therapeutics during the 4th quarter worth $36,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Sionna Therapeutics in the second quarter valued at about $45,000. Finally, Balyasny Asset Management L.P. bought a new position in Sionna Therapeutics in the fourth quarter valued at about $58,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.